While over-treating still remains a major problem in addressing prostate cancer, science continues to improve the task of identifying which patients actually need treatment as well as clarifying what treatments are most appropriate. The prostate-specific antigen (PSA) screening test still remains a stable tool physicians use to help detect prostate cancer, but an array of new biomarkers designed for various stages of prostate cancer have made their way into the market, which has proven to be fertile ground for young companies. (SeeAlso see "Prostate Cancer: Dissatisfaction With Current Diagnostics Drives Interest In Innovation" - Medtech Insight, 21 April, 2015..) As with most new products in health care, the key to successful adoption is not only a positive effect on patient outcomes, but also a proven ability to reduce costs, and without those elements payer reimbursement can be difficult to obtain.
Genetic Biomarkers Offer New Hope In Identifying Prostate Cancer
Although physicians still struggle with the best ways to treat patients suspected of having prostate cancer, a new group of genetic-based tests could provide new tools that will help improve diagnostic accuracy. These new biomarkers offer hope in reducing the number of patients who receive unnecessary treatment for cancers that are not actually present in their bodies and for those cancers not aggressive enough to cause harm.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
Swiss medtech exporters seek urgent diplomatic action from the Swiss Federal Council in a bid to overturn the 2 April US decision to put tariffs on goods imports.
Beyond the US market, Monogram is actively pursuing regulatory approvals abroad, with India as a key target. The company has partnered with Shalby Hospitals, one of India’s largest orthopedic hospital networks, to conduct clinical trials and accelerate regulatory clearance in the region.
